Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356588 | 1.00 | NAMPT (0.57) | NAMPTALDH1A1LMNAMAPTCYP2C9 | |
| SCHEMBL20417735 | 0.79 | MAPT (0.68) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL1156395 | 0.75 | TP53 (0.65) | NAMPTALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6864420 | 0.75 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL4121234 | 0.75 | CCR2 (0.72) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL31599460 | 0.75 | CCR2 (0.72) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL4125434 | 0.74 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL7426326 | 0.74 | NTRK1 (0.50) | NAMPTALDH1A1LMNAMAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL4119324 | 0.74 | CCR2 (0.71) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL3056166 | 0.73 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104822267-A | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | BARUCH S BLUMBERG INST | 2015-08-05 | — | — | CN | claimed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | claimed |
| EP-2819671-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | Baruch S. Blumberg Institute (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130703-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-09-06 | — | — | WO | claimed |
| US-20260062486-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4653462-A2 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | Arbutus Biopharma Corporation (CA) | 2025-11-26 | — | — | EP | disclosed |
| US-11904052-B2 | Methods for ameliorating infusion reactions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-20 | — | — | US | disclosed |
| US-20240052349-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240050463-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4240369-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| CN-116472063-A | Targeted conjugates comprising modified siRNAs | 阿布特斯生物制药公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230060006-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-02-23 | — | — | US | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| CN-104822267-A | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | BARUCH S BLUMBERG INST | 2015-08-05 | — | — | CN | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| EP-2819671-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | Baruch S. Blumberg Institute (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130703-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130703-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050463-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | HAVCR2, FABP1, HDGF | NAMPT 1151/4885ALDH1A1 1757/4885LMNA 1195/4885 |
| US-11904052-B2 | Methods for ameliorating infusion reactions | IL2, CD47, IL5 | NAMPT 1882/4885ALDH1A1 1351/4885LMNA 3845/4885 |
| US-20240052349-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | SNRPE, AGO2, DCLRE1A | NAMPT 987/4885ALDH1A1 1393/4885LMNA 2316/4885 |
| US-20260062486-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | PDCD1, CD274, PDCD4 | NAMPT 1124/4885ALDH1A1 1489/4885LMNA 371/4885 |
| US-20230060006-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | IL2, CD47, IL5 | NAMPT 1882/4885ALDH1A1 1351/4885LMNA 3845/4885 |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | HAVCR2, PCNA, DNMT1 | NAMPT 932/4885ALDH1A1 4030/4885LMNA 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.